Abstract:Abstract Background: In the past 20 years, the efficacy and prognosis of HER2-positive breast cancer have significantly improved. However, nearly 50% of patients still have residual invasive tumors after chemotherapy combined with dual-targeted neoadjuvant therapy, especially for those with disease progression during treatment. A lack of effective therapeutic regimens results from the failure of targeted therapy, whose heterogeneity is especially worthy of our attention. The aim of this study was to look for efficacy markers and investigate new drug-resistance mechanisms. Methods: Firstly, the high-throughput sequencing data from 81 patients who received neoadjuvant chemotherapy TCbH (paclitaxel + carboplatin + trastuzumab) was analyzed by the efficacy outcomes. They were divided into 8 patients with stable or progressive disease (SD/PD), 35 with partial response (PR), and 38 with pathological complete remission (pCR). Then, UBE2E3 was chosen from the different expression genes between SD/PD and pCR based on efficacy results and the weighted gene co-expression network (WGCNA). UBE2E3 clinical correlations were investigated using publicly available data from The Cancer Genome Atlas (TCGA) and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC), and UBE2E3 was validated using immunohistochemistry (IHC) on 200 HER2-positive breast cancer tissue chips. Further, the UBE2E3 knockdown and overexpression stable transfer cell lines were constructed, and the effects of UBE2E3 on cell proliferation, clone formation, and drug sensitivity were verified by live cell imaging, the CCK8 assay, plate cloning, and IC50 assays, respectively. The tumor growth of UBE2E3 in vivo was investigated by an in situ transplantation tumor assay in nude mice. Meanwhile, the p-RB assay of mouse tissues by IHC was used to explore the effect of UBE2E3 on cell proliferation. RNA-seq was used to screen the downstream molecules of UBE2E3. Western blotting was used to verify the results of bioinformatics analysis and to explore the downstream key molecules. The protease inhibitor MG132 and actinomycin CHX were used to look at the effect on the stability of the target protein. Immunoprecipitation and silver staining assays were used to find interacting proteins with the UBE2E3. Results: Ten hub-genes which were efficacy-related were identified by WGCNA analysis, in which UBE2E3 was highly expressed in the SD/PD group (p < 0.05). In HER2-positive breast cancer, high expression of UBE2E3 was associated with poor prognosis and decreased disease-free survival both in public data and Fudan University Shanghai Cancer Center (FUSCC) data [HR 2. 36, (1.25–4.47), p < 0.05]. The experimental results demonstrated that UBE2E3 promoted the proliferation of HER2-positive breast cancer cells, enhanced clone formation, and resisted lapatinib’s treatment in cellular phenotype; and that UBE2E3 promoted tumor growth in vivo and upregulated the expression of p-RB. The differentially expressed genes’ sets of the RNA-seq between overexpressed cell lines and control showed that overexpressing UBE2E3 activated the EGFR pathway. Further, an immunoblot assay confirmed that UBE2E3 positively regulated EGFR levels and activated the downstream MAPK pathway. The proteasome inhibitor MG132 and CHX assays showed that UBE2E3 could stabilize EGFR proteins. The co-immunoprecipitation and silver staining assays showed that UBE2E3 stabilized EGFR proteins by interacting with c-Cbl. Conclusion: UBE2E3 could negatively affect the efficacy of HER2-positive breast cancer therapy and is significantly associated with poor prognosis. UBE2E3 may serve as a potential marker of efficacy and prognosis for HER2-positive breast cancer in the future. Therapeutic efficacy is affected by UBE2E3, which binds to c-Cbl and causes upregulation of EGFR expression in vivo, which in turn causes the MAPK pathway to be activated and tumor growth to be pushed up. Citation Format: Pei Li, Wei-Ru Chi, Bingqiu Xiu, Qi Zhang, Liyi Zhang, Ming Chen, Jingyan Xue, Xiaoyan Huang, Yayun Chi, Jiong Wu. UBE2E3 promotes the progression of HER2-positive breast cancer and influences the efficacy of targeted therapy via EGFR stabilization [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P5-02-41.

[Effect of UBE2C Overexpression on the Proliferation of 293T Cell Line].

Expression of recombinant BC047440 protein and its effects on proliferation of HepG2 cells in vitro

Establishment of Over-Expressing ERCC1 Protein Cell Line

Elevated Expression of Ube2t in Lung Cancer Tumors and Cell Lines

UBE2T Promotes Proliferation Via G2/M Checkpoint in Hepatocellular Carcinoma

Overexpression of UBE2D3 Gene in Esophageal Carcinoma Cell Line EC109 Can Influence the Proliferation, Migration and the Sensitivity to Cisplatin

Abstract P5-02-41: UBE2E3 Promotes the Progression of HER2-positive Breast Cancer and Influences the Efficacy of Targeted Therapy Via EGFR Stabilization

UBE2T Silencing Suppresses Proliferation and Induces Cell Cycle Arrest and Apoptosis in Bladder Cancer Cells.

The Effect of Up-Regulation of UTX Gene Expression on Renal Cancer Cell Line 786-O Proliferation

UBE2M Promotes Cell Proliferation Via the Β-Catenin/cyclin D1 Signaling in Hepatocellular Carcinoma

Construction of Plasmid of B Lymphocytes/leukemia-2 and Its Expression and Function in U251 Cells

Effects of overexpression of ErbB-3 binding protein Ebpl on growth and proliferation of NIH3T3 cells

UBE2D3 Gene Overexpression Increases Radiosensitivity of EC109 Esophageal Cancer Cells in Vitro and in Vivo.

Effects of over expression of ErbB-3 binding protein Ebp1 gene on growth and proliferation of HepG2 cells in human

Effects of recombinant plasmid of pEGFP -N1 -CNTN1 on proliferation,clone formation,migration and invasion of Hs578T cells

UBE2C Functions as a Potential Oncogene by Enhancing Cell Proliferation, Migration, Invasion and Drug Resistance in Hepatocellular Carcinoma Cells.

Ubiquitin-conjugating Enzyme E2T(UBE2T) Promotes Colorectal Cancer Progression by Facilitating Ubiquitination and Degradation of P53.

Elevated Expression of UBE2T Exhibits Oncogenic Properties in Human Prostate Cancer.

Effect of Estrogen Receptor 2 on the Cell Proliferation in Prostate Cancer Cell Line PC-3M

[Construction Eukaryotic Plasmids of the Urei and Ctb-Urei and Profile Its' Expression in Cell].

Construction of Set Overexpression Vector and Its Effects on the Proliferation and Apoptosis of 293t Cells